Based on these papers, we found that accreta placentation has been reported to be associated with changes in the levels of established maternal serum biomarkers including biomarkers previously used for the screening fetal neural tube defects (AFP) and aneuploidy (free β‐hCG) (Figure S1) and new biomarkers used more recently for the screening preeclampsia and fetal growth restriction (PlGF, PAPP‐A) (Table 1; Table S1). The gene discussed is PAPPA; the disease is preeclampsia.